

1 Development of a Novel Medium Throughput Flow-Cytometry Based  
2 Micro-Neutralisation Test for SARS-CoV-2 with Applications in  
3 Clinical Vaccine Trials and Antibody Screening

4 Sophie O'Reilly<sup>1</sup>, Grace Kenny<sup>1,2</sup>, Tamara Alrawahneh<sup>1</sup>, Nathan Francois<sup>1</sup>, Matthew Angeliadis<sup>1</sup>,  
5 Valentin de Masson d'Autume<sup>1</sup>, Alejandro Garcia Leon<sup>1</sup>, Eoin R. Feeney<sup>1,2</sup>, Obada Yousif<sup>3</sup>, Aoife  
6 Cotter<sup>1,4</sup>, Eoghan de Barra<sup>5,6</sup> Mary Horgan<sup>7</sup>, Patrick WG Mallon<sup>1,2</sup>, Virginie Gautier<sup>1</sup>

7 <sup>1</sup>Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4,  
8 Ireland

9 <sup>2</sup>Department of Infectious Diseases, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland

10 <sup>3</sup>Endocrinology Department, Wexford General Hospital, Carricklawn, Wexford, Ireland

11 <sup>4</sup>Department of Infectious Diseases, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland

12 <sup>5</sup>Department of Infectious Diseases, Beaumont Hospital, Beaumont, Dublin 9, Ireland

13 <sup>6</sup>Department of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland

14 <sup>7</sup>Department of Infectious Diseases, Cork University Hospital, Wilton, Co Cork, Ireland

15 Corresponding Author: Virginie Gautier [Virginie.gautier@ucd.ie](mailto:Virginie.gautier@ucd.ie)

16

17

18

19

20

21

22

23

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 24 **Abstract**

25 Quantifying neutralising capacity of circulating SARS-COV-2 antibodies is critical in evaluating  
26 protective humoral immune responses generated post-infection/post-vaccination. Here we describe a  
27 novel medium-throughput flow cytometry-based micro-neutralisation test to evaluate Neutralising  
28 Antibody (NAb) responses against live SARS-CoV-2 Wild Type and Variants of Concern (VOC) in  
29 convalescent/vaccinated populations. Flow Cytometry-Based Micro-Neutralisation Test (Micro-NT)  
30 was performed in 96-well plates using clinical isolates WT-B, WT-B.177.18 and/or VOCs Beta and  
31 Omicron. Plasma samples (All Ireland Infectious Diseases (AIID) Cohort) were serially diluted (8  
32 points, half-log) from 1/20 and pre-incubated with SARS-CoV-2 (1h, 37°C). Virus-plasma mixture  
33 were added onto VERO E6/VERO E6 TMPRSS2 cells for 18h. Percentage infected cells was analysed  
34 by automated flow cytometry following trypsinisation, fixation and SARS-CoV-2 Nucleoprotein  
35 intracellular staining. Half-maximal Neutralisation Titres (NT50) were determined using four-  
36 parameter logistic regression. Our assay was compared to Plaque Reduction Neutralisation Test (PRNT)  
37 and validated against WHO anti-SARS-CoV-2 Immunoglobulin Standards. Using WHO Standards with  
38 low, medium or high anti-SARS-CoV-2 IgG, both Micro-NT and PRNT achieved comparable NT50  
39 values. Micro-NT was found to be highly reproducible (inter-assay CV of 11.64%). Screening 190  
40 convalescent samples and 11 COVID-19 naive controls (AIID cohort) we demonstrated that Micro-NT  
41 has broad dynamic range differentiating NT50s <1/20 to >1/5000. We could also characterise immune-  
42 escape VOC observing up to 10-fold reduction in NT50 against SARS-CoV-2 Beta variant. Our flow  
43 cytometry-based Micro-NT is a robust and reliable assay to quantify NAb titres, and has been selected  
44 as an endpoint in clinical trials. It has higher throughput (96 well format versus 12 well) and reduced  
45 infection time (18h vs 48-96h) compared to the gold standard PRNT.

## 46 **Abbreviations**

47 S=Spike, NP=Nucleoprotein, NAbs= Neutralising Antibodies, RBD=Receptor Binding Domain, ACE-  
48 2=Angiotensin-Converting Enzyme 2, WT=Wild-Type, VOC=Variant of Concern, PRNT=Plaque  
49 Reduction Neutralisation Test, CPE=Cytopathic Effects, NT50=50% Neutralisation Titre.

## 50 **Introduction**

51 SARS-CoV-2 is the viral agent responsible for the Coronavirus Infectious Disease 2019 (COVID-19)  
52 pandemic (1) . The disease was given pandemic status by the World Health Organisation in March  
53 2020, and as of August 2022, there has been 600 million cases, and 6.5 million deaths (2).

54 Both T-cell and humoral immune responses are required for protection from COVID-19. Humoral  
55 immunity relies on B cell exposure to SARS-CoV-2 antigens, which triggers their proliferation into  
56 antibody secreting plasma cells (3). Following infection, antibodies are produced against SARS-CoV-  
57 2 viral proteins, predominantly the Spike (S) and the Nucleocapsid Protein (NP) (4, 5). Neutralising  
58 antibodies (NAbs) are a subset of SARS-CoV-2 antibodies that prevent viral entry, through either direct  
59 blocking of virus binding to the host cell receptor, or preventing conformational changes required for  
60 membranes fusion. SARS-CoV-2 NAbs target the S protein, making it the preferred COVID-19 vaccine  
61 candidate (6, 7) .

62 The S protein is comprised of trimeric S1/S2 heterodimers. S1, harbouring an N-terminal domain and  
63 a Receptor Binding Domain (RBD), interacts with the host cell through binding of the RBD to the  
64 angiotensin-converting enzyme 2 (ACE-2) receptor. Following S1/S2 cleavage by host cell proteases  
65 including furin, S2' cleavage by TMPRSS2 or Cathepsin-L mediates membrane fusion and cell entry  
66 (8). The most potent NAbs target the RBD as these directly compete with ACE-2 for binding. Mutations  
67 in this site are often associated with immune escape (9). Non-RBD sites are more evolutionarily  
68 conserved, so NAbs targeting these sites can often maintain efficacy against SARS-CoV-2 variants as  
69 well as display cross-reactivity with other sarbecoviruses (10) .

70 An effective antibody response provides protection against COVID-19. 'The Protective Neutralisation  
71 Classification Model' described by (6) suggests that the protective neutralisation titre (reducing risk of  
72 infection by 50%) is 20% of the mean neutralisation titre of a convalescent cohort, which they have  
73 found to strongly predict protective immunity (against symptomatic disease) elicited by COVID-19  
74 vaccine trials, while achieving a titre of only 3% of the mean is sufficient to reduce risk of severe disease  
75 by 50%.

76 Not all S-targeting antibodies are neutralising. Post-infection or post-vaccination, a polyclonal antibody  
77 population is produced, targeting sites along the S protein (11). Some may only bind, but not have any  
78 neutralising capacity due to their site of action. Others may offer protection against Wild-type (WT)  
79 SARS-CoV-2, the strain against which the vaccine S is modelled, but not against immune-escape  
80 Variants of Concern (VOC), including Beta and Omicron, which have amino acid mutations in key  
81 antibody binding sites in the RBD (12) . For this reason, an antibody titre, the measure of total anti-  
82 SARS-CoV-2 IgGs against a certain target present in a sample (13), is not sufficient to infer a protective  
83 immune response. Instead, the functional capacity of an antibody population can be determined using a  
84 neutralisation test.

85 Neutralisation tests, used to measure the capacity of a monoclonal antibody or plasma/serum to inhibit  
86 viral infection of susceptible cells, have proved valuable in elucidating SARS-CoV-2 antibody  
87 responses over time (14), in convalescent versus vaccinated individuals (15), and against SARS-CoV-  
88 2 VOCs (16) (17). This information is critical to forming effective public health strategies, from  
89 understanding when vaccine-induced protection wanes in different cohorts to devise booster strategies  
90 (18, 19), to identifying plasma donors for convalescent therapy (20, 21), to rapid identification of new  
91 VOCs that escape pre-existing immunity (22, 23).

92 The gold standard viral neutralisation assay is the Plaque Reduction Neutralisation Test (PRNT) (24).  
93 Here, live SARS-CoV-2 is co-incubated with serially diluted antibodies to facilitate neutralisation, and  
94 the virus is then used to infect a monolayer of cells. Over days, infected cells will display viral  
95 cytopathic effects (CPE) and die, leaving visible plaques in the monolayer that can be quantified to  
96 determine the reduction in infectious titre associated with the dilution factor of antibodies. However,  
97 this technique has several limitations which alternative assays have been developed to address. These  
98 include the large surface area for plaque formation requiring large wells, typically 6- or 12-well, which  
99 limits the throughput. The time to develop visual plaques can be up to 5 days for SARS-CoV-2.  
100 Furthermore, plaque counting is often done by eye, and even with automated software can be error-  
101 prone and subjective.

102 To address the low throughput, several assays have been adapted from PRNT, firstly facilitating  
103 neutralisation with a co-incubation of virus and antibodies, followed by determining the effectiveness  
104 of neutralisation through infection of susceptible cells. The key difference in these assays are the format  
105 (96-well plates) and the endpoints (Table 1). Rather than wait for visible plaques, micro-foci can be  
106 detected in the monolayer after only 18-hrs infection by staining of viral antigens (24, 25). Alternatively,  
107 recombinant SARS-CoV-2 virus expressing Green Fluorescent Protein can be detected directly without  
108 the need for further processing (25). Another approach is to detect viral genetic material in cell lysates  
109 through RT-qPCR following RNA extraction (26, 27) or to quantify replicating virus (viral load) by  
110 enzyme-linked immunosorbent assay (ELISA) (28). Other assays score the presence or absence of CPE  
111 under a microscope (29, 30) using a cell imager (31), or using colorimetric cellular dyes (29) . All these  
112 assays have the advantage of being medium to high throughput, suitable for 96-well plates, and rapid  
113 compared to PRNT. However, they still have limitations. Foci-based assays can have difficulty  
114 separating spots that are close together, CPE is subjective and slow to develop, recombinant virus is  
115 time consuming to develop and validate to rapidly address new variants, and RT-qPCR is costly.

116

117

118

119

120

121

122

123

124

125

126 **Table 1:** Comparison of Micro-Neutralisation Tests.

| Micro-Neutralisation Assays   | Assay Endpoints                                       | Infection time | Overlay required | Quantitative | Viral/Cellular Target                        | Reference     |
|---|---|----------------|------------------|--------------|--|---------------|
| Flow Cytometry Based Micro-NT   | Flow Cytometry  | 18-hrs         | No               | Yes          | Intracellular SARS-CoV-2 NP                  | (This report) |
| ELISA-based virus neutralisation assay                                      | Enzyme-linked immunosorbent assay (ELISA)             | 24 hrs         | No               | Yes          | Intracellular SARS-CoV-2 NP                  | (28)          |
| qRT-PCR-based virus neutralization assay                                    | RT-qPCR   | 24 hrs         | No               | Yes          | Intracellular SARS-CoV-2 genomic RNA         | (26,27)       |
| Microneutralization assay (MNA)/ Focus reduction neutralization test (FRNT) | Infected foci measured by computer-controlled imagers | 22-24 hrs      | Yes              | Yes          | Cell-membrane associated SARS-CoV-2 Spike    | (24, 25)      |
| mNeonGreen-based FRNT (FRNT-mNG)  | Fluorescent ELI-SPOT                                  | 24-hrs         | Yes              | Yes          | mNeonGreen expressing recombinant SARS-CoV-2 | (25)          |
| Virus Neutralisation Test (VNT)   | CPE observed under light microscope                   | 5 days         | No               | No           | CPE  | (30)          |
| Colorimetric cytopathic effect-based microneutralization assay              | Optical density of cellular lysate                    | 3 days         | No               | Yes          | CPE proxy                                    | (29)          |
| High-content fluorescent live SARS-CoV-2 neutralization assay               | Nuclei counts using IN CELL analyser                  | 3 days         | No               | Yes          | CPE proxy                                    | (31)          |

127  
128 Table 1: Comparison of Micro-Neutralisation Tests. Micro-NTs are conducted in medium-throughput  
129 formats, typically 96-well plates. Following neutralisation of live SARS-CoV-2 by serial dilutions of  
130 plasma/serum, neutralisation capacity of each dilution is determined by corresponding infection levels  
131 compared to controls. The primary difference is the endpoint used to quantify infection, which may  
132 measure viral production directly, or viral cytopathic effects (CPE).

133  
134 One significant limitation of PRNT, is the use of live SARS-CoV-2. This means the assays must be  
135 carried out in Containment Level 3 facilities, by highly trained staff. Pseudovirus assays, where a viral  
136 backbone from vesicular stomatitis virus (VSV) or lentivirus, is engineered to express the SARS-CoV-  
137 2 S protein, have become popular choice as they only require Containment Level 2 facilities (32) .  
138 However, they focus on the impact of S protein independently of other SARS-CoV-2 proteins present  
139 at the viral membrane and typically only measure viral entry, while live-virus neutralisation assays can  
140 monitor several rounds of replication. As the virus can spread cell-to-cell post-entry, it may evade  
141 neutralisation, thus explaining the lower neutralisation titres observed in such assays compared to  
142 pseudovirus assay (33). Surrogate Viral Neutralisation Tests or competitive immunoassays where  
143 antibodies prevent interaction between recombinant viral Spike protein and ACE-2 receptor *in vitro*  
144 have been proposed as a user-friendly method of inferring neutralisation capacity in the absence of  
145 virus, however they have shown poor correlation with PRNT (34) .

146 Here we aimed to develop a novel neutralisation assay suitable for medium-throughput screening of  
147 SARS-CoV-2 antibodies. We chose a live virus assay, which most closely reflects *in vivo* neutralisation,  
148 as all viral proteins are present and complete. Instead of using a CPE-based approach, we used flow  
149 cytometry to quantify individual infected cells based on intracellular SARS-CoV-2 NP staining. This  
150 assay uses a 96-well plate format, for processing of up to 36-samples per day. It does not require  
151 washing the cells post-infection or adding an overlay, reducing hands-on processing time. The duration  
152 of infection is only 18-hrs allowing rapid turn-around of results, and the output is quantitative (%  
153 infected cells per well), less subjective than plaque or CPE-based assays.

154 This novel live SARS-CoV-2 flow-cytometry based micro-neutralisation test (Micro-NT) was  
155 calibrated and validated using WHO SARS-CoV-2 IgG standards and showed comparable  
156 neutralisation titres to PRNT. We show a high reproducibility of the assay and a broad dynamic range  
157 of neutralisation titres across a COVID-19 convalescent cohort. Finally, Micro-NT can immune escape  
158 of VOCs (Beta and Omicron-BA.5) compared to WT SARS-CoV-2 using the same plasma samples.

## 159 **Results**

160 Here we aimed to develop a medium-throughput, rapid-turnaround live-virus Neutralisation Assay, to  
161 enable screening of large clinical cohorts for COVID-19 vaccine studies, COVID-19 trials for  
162 convalescent plasma therapy, or monoclonal antibody studies. The assay involves 5 steps (Figure 1).  
163 Firstly, serum from convalescent or vaccinated individuals is heat inactivated and serially diluted.  
164 Secondly, the antibody dilutions are co-incubated with live SARS-CoV-2 (viral neutralisation). Thirdly,  
165 the virus/antibody mixture is used to infect cells in culture. Next, cells are trypsinised and fixed,  
166 followed by intracellular staining and flow cytometry. Finally, the data is analysed to find the  
167 Neutralisation Titre resulting in a 50% inhibition of infection (NT50). The NT50 can then be used to  
168 easily compare the neutralisation capacities of human plasma between individuals, before or after  
169 vaccination, or against different SARS-CoV-2 variants.

## 170 **1. Flow Cytometry-Based Micro-NT Workflow**

171 Step 1: Plasma is heat inactivated for 30 mins at 37°C. This ensures inactivation of the complement  
172 system which can trigger cytolysis. For clinical trials, or when multiple experiments are planned per  
173 sample, after heat-inactivation the plasma can be aliquoted and stored at -80°C, to avoid multiple freeze-  
174 thaw events. Optional: prior to dilution, the samples can be filter-sterilised (0.25µM filter). If working  
175 with low volumes, this can be done after diluting the serum 1/20 in Infection Medium, and then  
176 proceeding with a half-log serial dilution (Figure 1). Minimum volume required is 10ul plasma for a  
177 test against a single variant, or 30ul against 3 variants (See Box 1 on sample processing).

---

### 178 **BOX 1: Maximising Sample Processing**

179 *Up to 12x96-well plates can be comfortably processed together where only the inner 60-wells of the*  
180 *plate are used, leaving the outer wells available to be filled with PBS, limiting evaporation from the*  
181 *wells, and avoiding the 'edge-effect'. The 96-well plate format allows for three samples to be run in*  
182 *parallel, in duplicate, on a single plate (Figure 1), with a total of 36 samples per day, or a single sample*  
183 *against three SARS-CoV-2 variants for a total of 12 samples per day.*

184 *Within 1 hour, 12 plasma samples can be serially diluted across 2x48-well plates, using a 300ul multi-*  
185 *channel pipette, and divided amongst 3x96-well plates for incubation with SARS-CoV-2. An adjustable*  
186 *tip spacing, 300ul multi-channel makes it easy to transfer from the 48-well format to the 96-well format.*  
187 *The neutralisation takes one hour at 37°C 5% CO<sub>2</sub>. A second hour of hands-on time is then required*  
188 *to replace the medium on the cells from culture medium to infection medium (100ul per well) and add*  
189 *100ul virus/plasma to the cells. As these are incubated in 96-well plates, this can easily be done with a*  
190 *standard or automated multi-channel pipette. This process takes 2-hrs for 12-plates.*

191 *Cells are trypsinised and transferred to round-bottom plates for fixation and staining. Transfer*  
192 *efficiency can be increased by using an electronic 1ml multi-channel pipette to serially dispense*  
193 *PBS/PFA across a full plate (Thermo Scientific #46300800). The percentage of infected cells is*  
194 *measured directly in 96-well plates through automatic flow-cytometric detection of intracellular SARS-*  
195 *CoV-2 N protein. Resuspending the cells in 60ul flow running buffer results in a run-time of 60-80 mins*  
196 *per plate, depending on instrument settings.*



197 Step 2: For viral neutralisation, plasma dilutions are co-incubated with an equal volume (1:1) live  
198 SARS-CoV-2 WT or VOCs for 1-hr at 37°C 5% CO<sub>2</sub>, to facilitate antibody-virus interaction (Figure 1).  
199 Step 3: Antibody-virus mixture is then added to sub-confluent Vero E6 or Vero E6/TMPRSS2 cells in  
200 96-well plates and the cells are incubated for 18-hrs in 37°C, 5% CO<sub>2</sub> (Fig 1.4). Controls include wells  
201 with no virus and virus alone. The SARS-CoV-2 variants used are fully infectious, capable of  
202 completing full replication and re-infection cycles, through cell-to-cell contact and also through release  
203 of infectious particles into the supernatant. 18-hrs is enough time for the cells to produce viral proteins  
204 abundantly, allowing for easy distinction of infected and non-infected cells during analysis, while not  
205 providing enough time for viral cytopathic effects to develop. This is important, as cells must be intact  
206 for subsequent staining and flow-cytometry analysis. See Box 2 for full details of the infectious model.

---

## 207 **BOX 2: SARS-CoV-2 Infectious Model**

208 *The assay was developed with Vero E6 cells or Vero E6/TMPRSS2 cells, as both express the ACE-2*  
209 *receptor, are highly permissive to SARS-CoV-2, and are a standard cellular model for SARS-CoV-2*  
210 *neutralisation assays (35-37). The cellular protease TMPRSS2 is a co-factor of SARS-CoV-2 entry*  
211 *expressed at the cell surface and important for membrane fusion. Its expression in Vero E6 enhances*  
212 *the rate of infection. Of note, amplification of SARS-CoV-2 on cells lacking the TMPRSS2 receptor can*  
213 *lead to a well-described cell-line adaption, whereby deletions or mutations in the furin-cleavage site,*  
214 *of 15-30bp at the S1/S2 cleavage site, allows the virus to become TMPRSS2-independent, in as few as*  
215 *two passages (38, 39). Furthermore, this deletion ( $\Delta$ Furin) can be associated with reduced*  
216 *neutralisation compared to viruses bearing an intact Spike sequence, possibly due to an increased*  
217 *particle to PFU ratio, resulting in more particles per infectious dose (40) .*

218 *When multiple SARS-CoV-2 variants are tested in parallel, the stock viruses are titrated to infect 30-*  
219 *40% of cells after 18-hrs, as measured by flow cytometry. This provides a large enough population of*  
220 *infected cells to observe the neutralisation of the virus across the plasma dilution series. Infection of*  
221 *the population saturates around 70% infected cells, and so infection in this range could bias the*  
222 *resulting neutralisation titre.*

---

223 Step 4: At 18-hrs post-infection, and following trypsinisation, the cells are resuspended in PBS with a  
224 final concentration of 4% Formaldehyde to facilitate cell fixation and viral inactivation following an  
225 incubation of 8-hrs in the dark. Cells should be processed as soon as possible but can be stored in  
226 Formaldehyde for up to 24-hrs in the dark at room temperature. In instances where immediate  
227 processing is not possible, formaldehyde should be replaced with PBS and plates can be stored at 4°C  
228 in the dark for up to one week, although this is not recommended. Once the virus is inactivated, the  
229 plates can be transferred to Containment Level 2 facilities to be permeabilised and stained for  
230 intracellular SARS-CoV-2 nucleoprotein (NP). Flow cytometry is then used to measure NP positive  
231 cells, as a percentage of the total gated live, single-cell population for each well (Figure 1). The gating  
232 strategy is described in detail in Box 3.

---

### 233 **BOX 3: Flow Cytometry Staining and Analysis Strategy**

234 *Here we use intracellular SARS-CoV-2 N as our target protein. As N is more conserved than Spike (41),*  
235 *the same antibody can be used to detect WT-B, WT-B.177.18, Beta and Omicron-BA.5 variants.*  
236 *Furthermore, as N is the most abundantly expressed SARS-CoV-2 protein, it can be detected as soon*  
237 *as 6-hrs post-infection and is clearly distinguishable from uninfected cells by 18-hrs post-infection.*  
238 *Furthermore, there is no homology to cellular proteins that might result in high background staining.*  
239 *Gating cells by Side Scatter (SSC) which indicates granularity, and Forward Scatter (FSC) which*  
240 *indicates size, allows viable cells to be distinguished from dead cells (low FSC, typical SSC) and*  
241 *cellular debris (low FSC and low SSC). Single cells can be separated from doublets or clumped cells*  
242 *by gating the FSC-Area against FSC-Height, which should be a linear relationship. We can then plot*  
243 *the live, single cells against FITC, which is the channel used to detect NP staining. Using our negative*  
244 *control wells (cells cultured in Infection Medium only, no virus) we gate to the immediate right of the*  
245 *cell population. As these cells should not contain any NP, <1% of cells should be considered positive.*  
246 *The same gate should then be applied to all wells. The positive controls (virus in Infection Medium, no*  
247 *plasma) should be checked to ensure there has been an appropriate level of infection.*

---

248 Step 5: Flow cytometry data can be exported as a CSV file for data analysis (Figure 1). Mean and  
249 standard deviation can be calculated for each well. Wells where there are <1000 live, single events do

250 not have enough cells to be representative of the population and should be removed from the analysis.  
251 Background level in the negative control wells should be subtracted from all the readings. The data can  
252 then be presented as a percentage of inhibition of infection, where the negative controls have 100%  
253 inhibition, and the positive controls have 0% inhibition. The NT50 can then be determined by a four-  
254 parameter non-linear regression.

## 255 **2. Micro-NT produced comparable Neutralisation Titres to PRNT**

256 We compared the NT50 values obtained using Micro-NT and conventional PRNT, as this is the gold  
257 standard viral neutralisation assay. We used WHO International Standard for anti-SARS-CoV-2  
258 immunoglobulin (human), a pool of eleven human plasma samples from convalescent patients with  
259 Low, Medium, or High titre SARS-CoV-2 S IgG, intended as a calibrant for serological assays. The  
260 neutralising capacity of the standards against WT-B SARS-CoV-2 on Vero E6 cells was measured using  
261 conventional PRNT (Figure 2A) or Micro-NT (Figure 2B). Both assays were able to distinguish Low,  
262 Medium, and High IgG titre standards based on their neutralising capacity. The NT50 values were  
263 determined for each standard and compared between assays. The NT50 for the low IgG standard was  
264 very similar between the two assays 86 for PRNT, versus 62 with Micro-NT (Figure 2C). Both assays  
265 produced the same NT50 with the Medium IgG standard (435 with PRNT and 431 with Micro-NT).  
266 Both assays found a high NT50 with the High IgG standard, with Micro-NT showing greater separation  
267 between the Medium and High Titre results than the PRNT assay (1144 with PRNT and 2962 with  
268 Micro-NT). Interestingly, the fold change between the medium and high results with Micro-NT closely  
269 reflected the fold change between the antibody potencies in IU/ml as provided by the WHO (7-fold  
270 increase between medium and high IgGs using WHO NT50s and 6.9-fold increase using Micro-NT  
271 NT50s).

## 272 **3. Micro-NT has good inter-assay and intra-assay reproducibility**

273 The Flow-Cytometry based Micro-NT assay reproducibility was determined by measuring Inter-Assay  
274 and Intra-assay variability. To determine the Intra-assay reproducibility, we ran 3 COVID-19  
275 convalescent plasma samples, with a low, medium or high NT50, each with an 8-point, half-log serial  
276 dilution (Figure 3A-3C). Each dilution was tested in 6 replicate wells on the same plate and the mean

277 and standard deviation calculated. The mean standard deviation was 1.76% across all 3 plates, with a  
278 range from 0.09% (mean infection 0.37%) to 3.57% (mean infection 49.2%), showing high intra-assay  
279 reproducibility.

280 3 naïve and 9 COVID-19 convalescent plasma samples were analysed using Micro-NT to determine  
281 the NT50 (Figure 3D). Each sample was tested using technical duplicates, in two independent  
282 experiments. The NT50 was determined for each experiment. The Mean and Standard Deviation was  
283 determined for each sample, and the co-efficient of variation (CV) measured (Standard  
284 Deviation/Mean). The mean CV was 11.64%, which shows high inter-assay reproducibility  
285 (Supplementary Table 1). The naive samples displayed no neutralising capacity (NT50<20).

#### 286 **4. Micro-NT has a broad Dynamic Range**

287 Across 190 convalescent plasma samples tested, we have found a broad range distribution of  
288 neutralising capacities, from 1 to >5000, without saturating the assay. The lower Limit of Detection  
289 (LOD) of the assay is an NT50 of 20, corresponding to the initial antibody dilution. Any sample unable  
290 to achieve a minimum of 50% inhibition with the initial dilution is given an arbitrary NT50 of 1. An 8-  
291 point, half-log dilution from 1/20, to 1/62927, provides an optimal range for measuring neutralising  
292 capacity against SARS-CoV-2 from convalescent (Figure 4A-4D) or vaccinated (data not shown)  
293 plasma samples.

#### 294 **5. Micro-NT can be used to Measure Modulation in Neutralising Capacity against SARS- 295 CoV-2 Variants of Concern**

296 To examine whether Micro-NT can identify and characterise immune-escape SARS-CoV-2 VOCs, we  
297 used the WHO SARS-CoV-2 IgG Standards in parallel to neutralise WT-B.177.18 SARS-CoV-2, and  
298 two VOCs, Beta and Omicron-BA.5 on Vero E6/TMPRSS2 cells (Figure 5A-C). When neutralised with  
299 Low IgG, WT-B.177.18 was the only variant neutralised (NT50 of 98.72), while neutralisation of Beta  
300 and Omicron-BA.5 was undetectable (Figure 5D). With Medium Titre IgG, all variants were neutralised  
301 (NT50s of 192.1, 31.94 and 31.38 respectively), though with a 6-fold decrease in capacity against Beta  
302 and Omicron-BA.5 compared to WT-B.177.18. With High Titre IgG, WT-B.177.18 remained the most  
303 effectively neutralised, with an NT50 of 919.7, while Beta and Omicron-BA.5 remained poorly

304 neutralised with a 4.5-fold decrease seen with Beta (NT50 of 203.4) and a 7.3-fold decrease seen with  
305 Omicron-BA.5 (NT50 of 125.4).

306 This flow-cytometry based Micro-NT is a medium throughput, reproducible, live SARS-CoV-2 assay,  
307 comparable to PRNT but suitable for screening large clinical cohorts for NAbs against SARS-CoV-2  
308 variants

### 309 **Conclusion**

310 Here we have introduced and presented in detail a new flow-cytometry-based Micro-Neutralisation  
311 Assay to quantify the neutralisation capacity of antibodies from plasma or serum. Live SARS-CoV-2  
312 is neutralised by antibodies from convalescent/vaccinated plasma and then used to infect Vero-E6/Vero-  
313 E6/TMPRSS2 cells in a 96-well plate format. After 18-hrs, cells are trypsinised, fixed and stained for  
314 intra-cellular SARS-CoV-2 NP. Flow cytometry is then used to quantify the % of infected cells per  
315 condition, which allows determination of the NT50 for each plasma sample, against WT SARS-CoV-2  
316 or VOCs.

317 This approach has been calibrated and validated against WHO SARS-CoV-2 IgG standards, using WT  
318 and VOCs. Using WT-B SARS-CoV-2, we have shown comparable NT50 titres obtained using PRNT,  
319 the gold standard for serological testing, and our flow-based Micro-NT, with the advantage of  
320 significantly increased throughput. This assay is medium throughput, capable of processing 3 samples  
321 per 96-well plate, with 12 plates being comfortably processed per day, simultaneously, for a total of 36-  
322 samples per day. The 18-hr infection duration is at the lowest end of the requirements for other micro-  
323 NTs (Table 1). Unlike CPE-based assays it directly measures infection through the detection of SARS-  
324 CoV-2 NP in infected cells, minimising risks of contamination or toxicity from serum/plasma being  
325 interpreted as viral-CPE. Similar to using well imagers to measure spot-forming units, flow cytometry  
326 quantifies the infection in each well, meaning a dose-response curve can be plotted allowing  
327 determination of the NT50.

328 Flow cytometry has several advantages as an assay endpoint. Firstly, infection is quantifiable, being  
329 able to see the number of infected cells as well as the percentage of the whole population. This is in  
330 contrast to a technique such as RT-qPCR where normalisation against a house-keeping gene is required

331 to interpret the data, or a CPE-based approach, where wells can be scored as positive or negative, but  
332 not on a gradient. Secondly, the size and granularity of the cell population is measured, allowing issues  
333 with viability or contamination to be quickly identified, that may not have been visible with a light  
334 microscope. Thirdly, a flow cytometer with an automatic plate reader will process all wells without  
335 requiring user input, other than set-up and cleaning, limiting hands-on processing time. Furthermore, as  
336 cells are fixed prior to staining, flow analysis can take place in CL2 conditions, when compact flow  
337 cytometers are placed within Biosafety Cabinets to control for risk of aerosol formation. This protocol  
338 expands the option to perform live cell neutralising assays to those with flow-cytometry facilities, which  
339 is becoming more common as labs are investing in this popular and diversely applicable technique.  
340 However, as with all live virus assays, limitations include access to CL3 facilities, with trained staff to  
341 carry out live virus work.

342 While pseudovirus assays performed in CL2 conditions can address some of these limitations, live-  
343 virus assays remain the gold standard. New VOCs can be rapidly isolated from nasopharyngeal swabs,  
344 and once validated, can be used directly in the assay. By titrating the viruses to infect the same % of  
345 cells after 18-hrs, neutralisation capacity can be determined against several SARS-CoV-2 variants in  
346 parallel, without needing to account for differences in CPE, or duration of time to development of CPE.  
347 The assay is also appropriate for testing antibodies from a variety of sources, including serum, plasma,  
348 or commercial monoclonal antibodies.

349 Flexibility in SARS-CoV-2 variants and antibody sources means the assay is easily adapted to multiple  
350 applications. We have used the flow-based Micro-NT to define an RBD titre post-infection/vaccination  
351 that correlates with a protective neutralisation titre (Kenny et al, in review) as well as to identify  
352 COVID-19 convalescent individuals as donors for convalescent plasma therapy. Another use will be  
353 measuring functional antibody production post-vaccination. During initial COVID-19 vaccine clinical  
354 trials, high infection and hospitalisation rates allowed for collection of data on protection from infection  
355 or severe disease (42-45) . Indeed, neutralisation titres post vaccination were found to be directly  
356 correlated with vaccine efficacy (46) . However, as vaccine uptake increases, and COVID-19 cases  
357 decrease, such clinical endpoints are harder to achieve. Surrogate endpoints, including neutralisation

358 titres will therefore play an important role in measuring vaccine efficacy in next generation vaccine  
359 trials (46, 47) . VACCELERATE, an EU Consortium is currently co-ordinating clinical trials  
360 identifying vaccine efficacy in elderly (ClinicalTrials.gov Identifier: NCT05160766) and paediatric  
361 populations (EudraCT Number: 2021-005043-71) as well as the safety, timing, and efficacy of COVID-  
362 19 booster vaccines in the fully vaccinated (EudraCT number 2021-004889-35). The flow-cytometry  
363 based micro-neutralisation assay described here was chosen to enable the measurement of NAbs across  
364 large numbers of clinical specimens (>400) across multiple SARS-CoV-2 variants.

## 365 **Methods**

### 366 **Cells**

367 Vero E6 (VERO C1008, Vero 76, clone E6, Vero E6), were obtained from ATCC (ATCC CRL-1587)  
368 and maintained in Dulbecco's Modified Eagle's Medium (DMEM, Thermo Scientific, 61965-026)  
369 supplemented with 10% Foetal Bovine Serum (Thermo Scientific, 10500-064) (DMEM-10). Vero  
370 E6/TMPRSS2 cells (#100978), obtained from the Centre For AIDS Reagents (CFAR) at the National  
371 Institute for Biological Standards and Control (NIBSC) (48) were cultured in DMEM supplemented  
372 with 10% Foetal Bovine Serum (FBS, DMEM-10) and Geneticin (Thermo Scientific, 10131035) at a  
373 concentration of 1mg/ml, at 37°C in 5% CO<sub>2</sub>. All cell lines routinely tested negative for mycoplasma.  
374 During the course of infection, cells were incubated in Complete Infection Medium, DMEM 2% FCS  
375 (DMEM-2) supplemented with Penicillin (1U/ml) and Streptomycin (100ug/ml) (Sigma-Aldrich,  
376 P4333) and amphotericin B (0.5ug/ml) (Thermo Fisher Scientific, 15290018)

### 377 **Human Plasma samples**

378 Plasma derived from ethylenediaminetetraacetic acid (EDTA) anticoagulated whole blood was collected  
379 from COVID-19 RT-qPCR positive and negative participants of the All-Ireland Infectious Disease  
380 (AIID) Cohort (49). For this analysis we included either individuals with polymerase chain reaction  
381 (PCR)-confirmed COVID-19, documented vaccination with 2 doses of mRNA-1273, BNT162b2 or  
382 ChAdOx1-S, at least 14 days from the second dose, or individuals without COVID-19 or vaccination  
383 recruited with available bio-banked plasma dated no later than July 2019, prior to the onset of the  
384 COVID-19 pandemic. A total of 190 convalescent plasma samples from COVID-19 patients were tested

385 in this study. 11 non-COVID-19 plasma samples, collected prior to the COVID-19 pandemic and  
386 negative for anti-SARS-CoV-2 antibodies were included as negative controls. Samples were stored at -  
387 80°C before use. All human plasma samples were heat-inactivated at 56°C for 30 minutes before testing.  
388 First WHO International Standard for anti-SARS-CoV-2 immunoglobulin, human (NIBSC code:  
389 20/136) is a pool of eleven human plasma from convalescent patients and was established in December  
390 2020 by the WHO Expert Committee on Biological Standardization.

### 391 **SARS-CoV-2 clinical isolates**

392 All work with live SARS-CoV-2 was carried out in Containment Level 3 laboratory under Biosafety  
393 Level 3 guidelines. WT Spike, Pango lineage B (WT-B) SARS-CoV-2 clinical isolate 2019-nCoV/Italy-  
394 INMI1, Clade V, Passage 4 (50) was obtained from the European Virus Archive goes Global (EVAg,  
395 Spallanzani Institute, Rome) and following its amplification on Vero E6 cells (Passage 6) contained a  
396 deletion in the Furin cleavage site. WT SARS-CoV-2 with D614G substitution (Pango lineage B.177.18  
397 (WT-B.177.18), GenBank accession ON350866, Passage 2), Beta (Pango lineage B.1.351, GenBank  
398 accession ON350868, Passage 2) and Omicron (Pango lineage BA.5 (Omicron-BA.5), GenBank  
399 accession OP508004, Passage 1) clinical isolates were isolated from SARS-CoV-2 positive  
400 nasopharyngeal swabs from the AIID cohort. Supernatant was filter sterilised (0.2µm filter) and diluted  
401 1:1 with Complete Infection Medium. Confluent Vero E6/TMPRSS2 cells were incubated with the  
402 virus in a T12.5 flask until 50% cell death was observed using a light microscope. The supernatant and  
403 cells were transferred to a confluent T175, with Complete Infection Medium. Cells were cultured until  
404 50% cell death was observed. The supernatant was collected and centrifuged at 4000xg for 5 minutes,  
405 aliquoted and stored at -80°C. The titre of the virus stocks was determined by median Tissue Culture  
406 Infectious Dose assay (TCID<sub>50</sub>) and/or plaque assay. Viral RNA was isolated using Qiagen Viral  
407 mRNA mini-kit according to manufacturer instructions. Viral RNA genome was sequenced to confirm  
408 the integrity of the Spike protein in each variant and lineage. Viral genomes were quantified by RT-  
409 qPCR amplification of the SARS-CoV-2 Nucleoprotein (N2) gene (RNA diluted 1 in 10 in nuclease-  
410 free water resulted in Ct values of 19.5, 21.1 and 20.1 for WT-B.177.18, Beta and Omicron-BA.5



411 variants, respectively. WT-B.177.18 had a titre of  $2.6 \times 10^6$  PFU per ml, Beta had a titre of  $1.2 \times 10^6$   
412 PFU/ml and Omicron-BA.5 had a titre of  $2.2 \times 10^6$  PFU/ml.

### 413 **Flow Cytometry-Based Micro-Neutralisation Assay**

#### 414 Viral Neutralisation

415 Heat-inactivated plasma samples were diluted with a half-log, 8-point serial dilution, from a starting  
416 dilution of 1 in 20 in Complete Infection Medium. SARS-CoV-2 isolates were titrated to infect 30-40%  
417 of Vero E6/Vero E6/TMPRSS2 cells 18-hr post infection as determined by flow cytometry analyses of  
418 SARS-CoV-2 Nucleoprotein positive cells. Viral isolates were diluted in Complete Infection Medium  
419 and co-incubated with the plasma dilutions in a 1:1 ratio for 1 hour at 37°C, 5% CO<sub>2</sub>.

#### 420 Infection

421 Vero E6 or Vero E6/TMPRSS2 cells were plated ( $2.5 \times 10^4$ ) the day before use in 100ul Culture Medium,  
422 in clear flat-bottom 96-well plates (Sarstedt, 83.3924). The cells were incubated overnight at 37°C 5%  
423 CO<sub>2</sub> to reach 90-100% confluency at time of infection. Post-neutralisation, supernatant was removed  
424 from the cells and replaced with 100ul Infection Medium and 100ul virus/plasma mix, in triplicates or  
425 duplicates. Positive controls (Virus alone) and Negative controls (Infection Medium alone) were  
426 included in each plate. Cells were incubated for 18 hours at 37°C 5% CO<sub>2</sub>.

#### 427 Cell collection

428 Supernatant was discarded and cells were rinsed with 100ul PBS. 25ul Trypsin-EDTA (Gibco, #  
429 25300054) was added to the cells at 37°C until single-cell suspension was obtained. Cells were  
430 resuspended in 75ul PBS and transferred to a round-bottom 96-well plate (Sarstedt, 83.3925500) with  
431 100ul 8% formaldehyde solution (Sigma Aldrich, F8775) to achieve a final concentration of 4%. Cells  
432 were fixed in the dark at room temperature for a minimum of 8 hours.

#### 433 Cell Staining

434 All steps-post fixation were carried out in Biosafety Level 2 laboratory in Class 2 Biosafety Cabinets.  
435 All centrifugation was carried out at 4000xg for 5 minutes (Heraeus Megafuge 16R, Thermo Scientific),

436 with 96-well plates contained within sealed buckets (Thermo Scientific, #75003625). The supernatant  
437 was removed, and cells were permeabilised with Perm/Wash Buffer (BD, 554723) according to  
438 manufacturer's instructions, which was maintained throughout antibody staining. Intracellular SARS-  
439 CoV-2 Nucleoprotein (NP) staining was performed with SARS/SARS-CoV-2 Nucleocapsid  
440 Monoclonal Antibody (E16C) (1/100 dilution, Invitrogen, MA1-7403), goat anti-mouse IgG2b-FITC  
441 (1/500 dilution, Santa Cruz Biotechnology, SC-2080).

#### 442 Flow Cytometry

443 Cells were resuspended in 60ul PBS-EDTA-2% for flow cytometry analysis (Beckman Coulter  
444 CytoFlex or CytoFlex S). Forward and Side-Scatter gates were used to exclude debris from intact cells.  
445 Cells were then gated using Forward Scatter Area where single cells were gated based on linearity  
446 between Area and Height, excluding doublets. % Infected cells of the single cell population were  
447 determined using the negative control wells to set the boundary of the negatively staining population in  
448 the FITC-channel (Blue 488nm laser, 525/40 filter). Gating was performed using CytExpert software  
449 (version 2.4.0.28, Beckman Coulter).

#### 450 Analysis

451 Wells with <1000 single events were excluded from analysis. Positive controls (virus only, no plasma)  
452 had to be >20% and <70% infected while negative controls (Infection Medium only) had to be <3% or  
453 the plate would be excluded from analysis. The mean % infected cells for each plasma dilution was  
454 calculated, and this result was normalised using the control wells, where 0% viral inhibition was equal  
455 to the positive control and 100% viral inhibition was equal to the negative control. The plasma dilution  
456 resulting in a 50% reduction in infection (NT50) was determined using logistical regression (4-  
457 paramater, variable slope) with GraphPad Prism (Version 9.3.1).

#### 458 **Plaque Reduction Neutralisation Test (PRNT)**

459 Vero E6 cells were plated ( $4.2 \times 10^5$ ) in 1ml DMEM-10 in clear flat-bottom 12-well plates. The cells  
460 were incubated overnight at 37°C 5% CO<sub>2</sub> to reach 100% confluency at time of infection. WHO SARS-  
461 CoV-2 IgG Standards with Low, Medium and High Titre IgG were diluted with a half-log, 8-point serial

462 dilution, from a starting dilution of 1 in 20 in Compete Infection Medium. SARS-CoV-2 (WT-B) was  
463 diluted in Complete Infection Medium to a concentration of 100 Plaque Forming Units (PFU) per 100ul  
464 and co-incubated with the WHO standard dilutions in a 1:1 ratio for 1 hour at 37°C 5% CO<sub>2</sub>. Supernatant  
465 was removed from the cells and 200ul plasma/virus was added to each well. Plate was gently shaken to  
466 ensure the surface of the well was evenly coated. The plates were incubated at 37°C 5% CO<sub>2</sub> for 90  
467 mins, with shaking every 10 mins. 2ml Complete Infection Medium with 1% carboxycellulose (CMC,  
468 Sigma #C5013) was added to each well. The plates were incubated for 96-hours until plaques became  
469 visible. 2ml 8% formaldehyde solution was added directly to each well to a final concentration of 4%  
470 and the plates were fixed for a minimum of 8 hours in the dark at room temperature. The supernatant  
471 was removed from the cells and the cells washed 3 times in ddH<sub>2</sub>O until all CMC was removed. Crystal  
472 violet (Sigma-Aldrich, #HT90132) 0.5% was added to just cover the surface of the well, incubated for  
473 15 mins at room temperature, then removed with 2 washes in ddH<sub>2</sub>O. Plates were allowed to fully dry  
474 before being photographed. A modified ImageJ script (51) was used to count the plaques per well and  
475 the duplicates were averaged and normalised to the positive control (virus only). The % inhibition per  
476 dilution was analysed with a non-linear regression (variable slope) on GraphPad Prism to determine the  
477 NT50.


## 478 **Acknowledgements**

479 SOR is the recipient of the Irish Research Council (IRC) Government of Ireland Postgraduate  
480 Scholarship (GOIPG/2019/4432). This study was supported by Science Foundation Ireland  
481 (20/COV/0305) and VACCELERATE, the European Corona Vaccine Trial Accelerator Platform. GK  
482 is funded through a fellowship from the United States Embassy in Ireland. The authors wish to thank  
483 all study participants and their families for their participation and support in the conduct of the All-  
484 Ireland Infectious Diseases Cohort Study.

485 The work has been performed with contribution or support of VACCELERATE participants.


486 The All-Ireland Infectious Diseases Cohort Study Investigators: Mater Misericordiae University  
487 Hospital: A. Cotter, E. Muldoon, G. Sheehan, T. McGinty, JS. Lambert, S. Green, K. Leamy. St  
488 Vincent's University Hospital: G. Kenny, K. McCann, R. McCann, C. O'Broin, S. Waqas, S. Savinelli,  
489 E. Feeney, PWG. Mallon. CEPHR: A. Garcia Leon, S. Miles, D. Alalwan, R. Negi. Beaumont Hospital:

490 E. de Barra, S. McConkey, K. Hurley, I. Sulaiman. University College Cork: M. Horgan, C. Sadlier, J.  
 491 Eustace. University College Dublin: C. Kelly, T. Bracken. Sligo University Hospital: B. Whelan, Our  
 492 Lady of Lourdes Hospital: J Low. Wexford General Hospital: O Yousif. University Hospital Galway:  
 493 B. McNicholas. St Luke's Hospital Kilkenny: G. Courtney. Children's Health Ireland: P. Gavin.




494

495 Figure 1: SARS-CoV-2 Flow Based Micro-Neutralisation Assay Workflow. 1. Heat inactivated (30  
 496 mins at 56°C) human plasma samples are serially diluted (8-point, half-log from 1/20) in Infection  
 497 Medium, in 48-well plates. 2. Viral neutralisation is done in 96-well plates, where each antibody dilution  
 498 is co-incubated with WT SARS-CoV-2 or a Variant of Concern (VOC) for 60 mins at 37°C. 3. Infection  
 499 of sub-confluent Vero-E6 or Vero-E6/TMPRSS2 cells with antibody-virus mixture is carried out in 96-  
 500 well plates for 18-hrs at 37°C. Each plate can test one plasma sample against 3 SARS-CoV-2 variants in  
 501 parallel, in duplicates, including controls (Virus alone and Infection Medium alone). 4. Cells are  
 502 trypsinised, fixed (4% formaldehyde for 8-hrs at room temperature), permeabilised and stained for  
 503 intracellular SARS-CoV-2 Nucleoprotein (NP). Infection is measured using Flow Cytometry, first  
 504 gating the live, single cell population, and then NP negative and positive populations. 5. Flow cytometry  
 505 data is analysed to determine the % of infected (NP+) cells per well and then the % of inhibition can be  
 506 determined by normalising each dilution to the positive and negative controls. NT50 can be determined  
 507 from the inhibition curve, as the dilution factor resulting in 50% inhibition of infection. Created with  
 508 BioRender.com




509

510 Figure 2: Validation of Flow-Based Micro-NT using WHO International SARS-CoV-2 IgG Standards  
 511 (A-B) SARS-CoV-2 (WT-B) was neutralised for 1 hour with an 8-point, half-log serial dilution of WHO  
 512 SARS-CoV-2 Low, Medium or High Titre IgG. (A) The antibody-virus mixture was then plated onto  
 513 Vero E6 cells for 90 mins before overlay (1% CMC) was added and incubated for 96-hours. Plaques  
 514 were quantified and the inhibition of infection is presented as a percentage, relative to the virus-only  
 515 control wells. Graph shows the mean and standard deviation of duplicates (n=1). (B) In parallel, the  
 516 virus-antibody mixture was added onto Vero E6 cells for 18-hrs before cells were trypsinised, fixed and  
 517 permeabilised, and stained for the SARS-CoV-2 NP. % of infected cells was determined by flow  
 518 cytometry analysis. Inhibition of infection is presented as percentage, relative to the virus-only control  
 519 wells. Graph shows the mean and standard deviation of duplicates (n=1). (C) Table shows the potency  
 520 of Neutralising antibodies present in WHO International SARS-CoV-2 IgG Standards with Low,  
 521 Medium and High titre IgG in International Units (IU/ml) as determined by the WHO. NT50 values  
 522 were determined for each standard by running in parallel on PRNT and Micro-NT, against SARS-CoV-  
 523 2 (WT-B) on Vero E6 cells. NT50 was determined using the percentage of inhibition for each dilution  
 524 factor, relative to the virus-only control and calculated from a non-linear regression (variable slope)  
 525 with Graph Pad Prism equal to the 50% Inhibitory Dilution (ID50).




526

527 Figure 3: Flow Cytometry-Based Micro-NT Intra- and Inter-Assay Variation (A-C) Data shows the %  
 528 infection across 8 dilutions of convalescent sera with (A) low, (B) mid, or (C) high neutralising capacity  
 529 against WT-B.177.18 SARS-CoV-2 on Vero E6/TMPRSS2 cells. Each dilution was tested in 6 wells  
 530 on a single plate, and the % infected cells in each well is shown. (D) NT50 values for 12 convalescent  
 531 serum samples against WT-B.177.18 SARS-CoV-2 were analysed using Micro-NT. Each dilution was  
 532 tested in duplicate, and each sample was run twice, independently. NT50 was determined using the  
 533 percentage of inhibition for each dilution factor, relative to the virus-only control and calculated from  
 534 a non-linear regression (variable slope) with Graph Pad Prism equal to the 50% Inhibitory Dilution  
 535 (ID50). Graph shows the NT50 values obtained for each sample (n=2).



536

537 Figure 4: Dynamic Range of Flow Cytometry-Based Micro-NT We analysed the NT50s of 190 COVID-  
 538 19 naïve or convalescent plasma samples, using Micro-NT, against SARS-CoV-2 (WT-B) on Vero E6  
 539 for 18-hrs. (A-D) Graphs show neutralising capacity of 3 convalescent plasma samples (P1-P3) across  
 540 8-point, half-log serial dilution, representative of samples with 50% Neutralisation Titres (NT50) within  
 541 a similar range. The percentage of viral inhibition of each dilution was calculated relative to the virus  
 542 only control. (E) Plasma from COVID-19 naïve individuals showed little or no neutralisation capacity  
 543 against SARS-CoV-2. (F) Graph shows all the NT50 values obtained across the cohort of COVID-19  
 544 convalescent plasma samples, measured using Micro-NT.



D.

| Antibody Titre | NT50<br>(WT-B.177.18) | NT50<br>(Beta) | NT50<br>(Omicron-BA.5) |
|----------------|-----------------------|----------------|------------------------|
| Low            | 98.72                 | 1              | 1                      |
| Medium         | 192.1                 | 31.94          | 31.38                  |
| High           | 919.7                 | 203.4          | 125.4                  |

545

546 Figure 5: Comparison of SARS-CoV-2 IgG Standards tested against SARS-CoV-2 Variants SARS-  
 547 CoV-2 WT-B.177.18, Beta and Omicron-BA.5 were neutralised for 1 hour with an 8-point, half-log  
 548 serial dilution of WHO SARS-CoV-2 (A) Low, (B) Medium or (C) High Titre IgG. The viruses were  
 549 plated onto Vero E6/TMPRSS2 cells for 18-hrs before cells were trypsinised, fixed and permeabilised,  
 550 and stained for the SARS-CoV-2 NP. % of infected cells was determined by flow cytometry analysis.  
 551 Inhibition of infection is presented as percentage, relative to the virus-only control wells. Graph shows  
 552 the mean and standard deviation of duplicates (n=1). (D) shows the NT50 values obtained for the WHO  
 553 International SARS-CoV-2 IgG Standards with Low, Medium and High titre IgG when run against WT-  
 554 B.177.18 SARS-CoV-2, and VOCs Beta and Omicron-BA.5. NT50 was determined using the  
 555 percentage of inhibition for each dilution factor, relative to the virus-only control and calculated from  
 556 a non-linear regression (variable slope) with Graph Pad Prism equal to the 50% Inhibitory Dilution  
 557 (ID50).

558

| NT50 (Rep 1) | NT50 (Rep 2) | NT50 (mean) | St. Dev | % CV   |
|--------------|--------------|-------------|---------|--------|
| 0            | 0            | 0           | 0       | 0.00%  |
| 0            | 0            | 0           | 0       | 0.00%  |
| 0            | 0            | 0           | 0       | 0.00%  |
| 65.37        | 51.64        | 58.505      | 6.865   | 11.73% |
| 74.04        | 77.47        | 75.755      | 1.715   | 2.26%  |
| 116.4        | 76.22        | 96.31       | 20.09   | 20.86% |
| 129          | 158.5        | 143.75      | 14.75   | 10.26% |
| 372.7        | 333.8        | 353.25      | 19.45   | 5.51%  |
| 302.2        | 636.5        | 469.35      | 167.15  | 35.61% |
| 376.3        | 785          | 580.65      | 204.35  | 35.19% |
| 1426         | 1637         | 1531.5      | 105.5   | 6.89%  |
| 3089         | 3653         | 3371        | 282     | 8.37%  |
|              |              |             | Mean    | 11.39% |

559

560 Supplementary Table 1: Inter-Assay Co-efficient of Variation Table shows the NT50 values obtained  
561 from 2 independent experiments of 12 convalescent COVID-19 plasma samples, as measured using  
562 Micro-NT against D614G SARS-CoV-2. Co-efficient of Variation (CV) was calculated as Standard  
563 Deviation (St. Dev)/Mean of Replicate 1 and 2 and displayed as a percentage. The % CV between plates  
564 is the average CV of all samples tested.

565

## 566 References

- 567 1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev*  
568 *Microbiol.* 2021;19(3):141-54.
- 569 2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real  
570 time. *Lancet Infect Dis.* 2020;20(5):533-4.
- 571 3. Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F. Antibody-mediated  
572 neutralization of SARS-CoV-2. *Immunity.* 2022;55(6):925-44.
- 573 4. Li K, Huang B, Wu M, Zhong A, Li L, Cai Y, et al. Dynamic changes in anti-SARS-CoV-2  
574 antibodies during SARS-CoV-2 infection and recovery from COVID-19. *Nat Commun.*  
575 2020;11(1):6044.
- 576 5. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. Longitudinal observation  
577 and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in  
578 humans. *Nat Microbiol.* 2020;5(12):1598-607.
- 579 6. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing  
580 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.  
581 *Nat Med.* 2021;27(7):1205-11.
- 582 7. Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S, Sampieri A,  
583 Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral  
584 Variants. *Front Immunol.* 2021;12:701501.
- 585 8. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and  
586 Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell.* 2020;181(2):281-92.e6.
- 587 9. Yi C, Sun X, Ling Z, Sun B. Jigsaw puzzle of SARS-CoV-2 RBD evolution and immune  
588 escape. *Cell Mol Immunol.* 2022;19(7):848-51.
- 589 10. Yuan M, Huang D, Lee CD, Wu NC, Jackson AM, Zhu X, et al. Structural and functional  
590 ramifications of antigenic drift in recent SARS-CoV-2 variants. *Science.* 2021;373(6556):818-23.
- 591 11. Wang C, van Haperen R, Gutiérrez-Álvarez J, Li W, Okba NMA, Albulescu I, et al. A  
592 conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-  
593 reactive monoclonal antibodies. *Nature Communications.* 2021;12(1):1-15.
- 594 12. Rössler A, Knabl L, von Laer D, Kimpel J. Neutralization Profile after Recovery from SARS-  
595 CoV-2 Omicron Infection. *N Engl J Med.* 3862022. p. 1764-6.



- 596 13. Kenny G, Negi R, O'Reilly S, Garcia-Leon A, Alalwan D, Gaillard CM, et al. Performance and  
597 validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection  
598 or vaccination. *J Immunol Methods*. 2022;113345.
- 599 14. Shim SM, Kim JW, Jung S, Jung Y, Woo HM, Yang JS, et al. Persistence of the neutralizing  
600 antibody response after SARS-CoV-2 infection. *Clin Microbiol Infect*. 2022;28(4):614.e1-.e4.
- 601 15. Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, et al. Infection and  
602 Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. *N Engl J*  
603 *Med*. 3852021. p. 664-6.
- 604 16. Sheward DJ, Kim C, Ehling RA, Pankow A, Castro Dopico X, Dyrdak R, et al. Neutralisation  
605 sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. *Lancet Infect Dis*.  
606 2022;22(6):813-20.
- 607 17. Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, et al. Increased memory  
608 B cell potency and breadth after a SARS-CoV-2 mRNA boost. *Nature*. 2022;607(7917):128-34.
- 609 18. Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, et al. Neutralizing antibody  
610 responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by  
611 breakthrough infection. *Sci Transl Med*. 2022;14(637):eabn8057.
- 612 19. Bruel T, Pinaud L, Tondeur L, Planas D, Staropoli I, Porrot F, et al. Neutralising antibody  
613 responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of  
614 BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study. *EClinicalMedicine*.  
615 2022;51:101576.
- 616 20. Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Convalescent plasma  
617 for hospitalized patients with COVID-19: an open-label, randomized controlled trial. *Nature Medicine*.  
618 2021;27(11):2012-24.
- 619 21. Sullivan DJ, Gebo KA, Shoham S, Bloch EM, Lau B, Shenoy AG, et al. Early Outpatient  
620 Treatment for Covid-19 with Convalescent Plasma. *N Engl J Med*. 2022;386(18):1700-11.
- 621 22. Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al. Escape of SARS-CoV-2  
622 501Y.V2 from neutralization by convalescent plasma. *Nature*. 2021;593(7857):142-6.
- 623 23. Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, et al. SARS-CoV-2  
624 Omicron is an immune escape variant with an altered cell entry pathway. *Nat Microbiol*.  
625 2022;7(8):1161-79.
- 626 24. Bewley KR, Coombes NS, Gagnon L, McInroy L, Baker N, Shaik I, et al. Quantification of  
627 SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization  
628 and pseudotyped virus neutralization assays. *Nature Protocols*. 2021;16(6):3114-40.
- 629 25. Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E, et al.  
630 Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2  
631 Neutralizing Antibodies. *Curr Protoc Immunol*. 2020;131(1):e116.
- 632 26. Abidi SH, Imtiaz K, Kanji A, Qaiser S, Khan E, Iqbal K, et al. A rapid real-time polymerase  
633 chain reaction-based live virus microneutralization assay for detection of neutralizing antibodies against  
634 SARS-CoV-2 in blood/serum. *PLoS One*. 2021;16(12):e0259551.
- 635 27. Lichtenegger S, Saiger S, Hardt M, Kulnik S, Wagner GE, Kleinhappl B, et al. Development  
636 of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout. *J Clin Microbiol*.  
637 2022;60(7):e0037622.
- 638 28. Frische A, Brooks PT, Gybel-Brask M, Sækmose SG, Jensen BA, Mikkelsen S, et al.  
639 Optimization and evaluation of a live virus SARS-CoV-2 neutralization assay. *PLoS One*.  
640 2022;17(7):e0272298.
- 641 29. Manenti A, Maggetti M, Casa E, Martinuzzi D, Torelli A, Trombetta CM, et al. Evaluation of  
642 SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization  
643 assay in human serum samples. *J Med Virol*. 2020;92(10):2096-104.
- 644 30. James J, Rhodes S, Ross CS, Skinner P, Smith SP, Shipley R, et al. Comparison of Serological  
645 Assays for the Detection of SARS-CoV-2 Antibodies. *Viruses*. 2021;13(4).
- 646 31. Tea F, Ospina Stella A, Aggarwal A, Ross Darley D, Pilli D, Vitale D, et al. SARS-CoV-2  
647 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. *PLoS Med*.  
648 2021;18(7):e1003656.
- 649 32. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Quantification of SARS-CoV-2 neutralizing  
650 antibody by a pseudotyped virus-based assay. *Nat Protoc*. 2020;15(11):3699-715.

- 651 33. Servellita V, Syed AM, Morris MK, Brazer N, Saldhi P, Garcia-Knight M, et al. Neutralizing  
652 immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. *Cell*.  
653 2022;185(9):1539-48.e5.
- 654 34. Saker K, Pozzetto B, Escuret V, Pitiot V, Massardier-Pilonchéry A, Mokdad B, et al. Evaluation  
655 of commercial Anti-SARS-CoV-2 neutralizing antibody assays in seropositive subjects. *J Clin Virol*.  
656 2022;152:105169.
- 657 35. Legros V, Denolly S, Vogrig M, Boson B, Siret E, Rigail J, et al. A longitudinal study of  
658 SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-  
659 19 severity. *Cell Mol Immunol*. 2021;18(2):318-27.
- 660 36. Muenza NA, García-Salum T, Pardo-Roa C, Avendaño MJ, Serrano EF, Levican J, et al.  
661 Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and  
662 previously infected individuals. *EBioMedicine*. 2022;78:103972.
- 663 37. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced  
664 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. *Cell*. 2021;184(16):4220-  
665 36.e13.
- 666 38. Sasaki M, Uemura K, Sato A, Toba S, Sanaki T, Maenaka K, et al. SARS-CoV-2 variants with  
667 mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient  
668 cells. *PLoS Pathog*. 2021;17(1):e1009233.
- 669 39. Lau SY, Wang P, Mok BW, Zhang AJ, Chu H, Lee AC, et al. Attenuated SARS-CoV-2 variants  
670 with deletions at the S1/S2 junction. *Emerg Microbes Infect*. 2020;9(1):837-42.
- 671 40. Johnson B, Xie X, Bailey A, Kalveram B, Lokugamage K, Muruato A, et al. Loss of furin  
672 cleavage site attenuates SARS-CoV-2 pathogenesis. *Nature*. 2021;591(7849).
- 673 41. Bai Z, Cao Y, Liu W, Li J. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral  
674 Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. *Viruses*.  
675 2021;13(6).
- 676 42. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of  
677 the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021;384(5):403-16.
- 678 43. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and  
679 Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *N Engl J Med*. 2021;384(23):2187-  
680 201.
- 681 44. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy  
682 of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383(27):2603-15.
- 683 45. Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and  
684 Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. *N Engl J Med*. 2021;385(25):2348-60.
- 685 46. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune  
686 correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science*.  
687 2022;375(6576):43-50.
- 688 47. Falsey AR, Frenck RW, Jr., Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-CoV-2  
689 Neutralization with BNT162b2 Vaccine Dose 3. *N Engl J Med*. 3852021. p. 1627-9.
- 690 48. Nao N, Sato K, Yamagishi J, Tahara M, Nakatsu Y, Seki F, et al. Consensus and variations in  
691 cell line specificity among human metapneumovirus strains. *PLoS One*. 2019;14(4):e0215822.
- 692 49. Mallon PWG, Tinago W, Leon AG, McCann K, Kenny G, McGettrick P, et al. Dynamic  
693 Change and Clinical Relevance of Postinfectious SARS-CoV-2 Antibody Responses. *Open Forum*  
694 *Infect Dis*. 2021;8(8):ofab122.
- 695 50. Capobianchi MR, Rueca M, Messina F, Giombini E, Carletti F, Colavita F, et al. Molecular  
696 characterization of SARS-CoV-2 from the first case of COVID-19 in Italy. *Clin Microbiol Infect*.  
697 2020;26(7):954-6.
- 698 51. Cacciabue M, Currá A, Gismondi MI. ViralPlaque: a Fiji macro for automated assessment of  
699 viral plaque statistics. *PeerJ*. 2019;7:e7729.

700